Teleflex Incorporated (TFX) Return on Assets ROA from the second quarter of 2026 to second quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Jun 30 2026 to Jun 29 2025 - CSIMarket
Teleflex Incorporated's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period
Return on Assets, Quarterly Results, Trends, Rankings, Statistics
What is Teleflex Incorporated's ROA in the second quarter of 2026?
Teleflex Incorporated had a negative return on assets (ROA) of -14.57%, due to the net loss of $-1 billion, during the twelve months ending in the second quarter of 2026.
However, within the Healthcare sector 332 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3325, from total ROA ranking in the first quarter of 2026 at 3836.
In an era marked by complex supply chain dynamics and rapidly shifting consumer demands, businesses are increasingly turning to innovative technology solutions to enhance their operational efficiency. A recent collaboration between Teleflex Incorporated, a global leader in medical technologies, and o9 Solutions, an enterprise AI software platform provider, exemplifies this trend. By opting for o9’s AI-powered tools, Teleflex aims to bolster its end-to-end integrated business planning and supply chain management capabilities, setting a new standard in the healthcare industry.Founded in Wayne, Pennsylvania, Teleflex has established itself as a crucial provider of therapeutic medical devices and technologies that improve patient outcomes. With a focus on quality and efficiency, the company understands the significance of having a robust supply chain strategy. As global demand for medical technologies has surged, propelled further by the COVID-19 pandemic, the importance of agile and responsive supply chains has never been clearer. In light of these challenges, Teleflex’s partnership with o9 Solutions emerges as a strategic move designed to fortify its supply chain operations.
Teleflex’s Titan SGS Stapler Shows Potential for Enhanced Clinical Outcomes and Increased Procedural Efficiency in Sleeve Gastrectomies: A Propensity Matched Analysis WAYNE, Pa., Aug. 21, 2024 Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, announced a recently published retrospective analysis of clinical data that links the Titan SGS Stapler with improved clinical outcomes and significant procedural efficiencies compared to traditional multi-fire surgical staplers used in laparoscopic sleeve gastrectomy (LSG). This groundbreaking study was conducted by a team of five surgeons at the MBSAQIP-accredited Corewell Health Hospital in Grand Rapids, MI, which is recognized as a Center of Excellence for bariatric surgery. The full research findings are available in the latest issue of Obesity Surgery . Study OverviewThe comparative analysis was centered on the proposition that the Titan SGS Stapler can offer more consistent and optimal results in gastric pouch formation than traditional staplers, which are more prone to variability. Propensity score matching was leveraged to equilibrate potential confounding variables, thereby providing robust data supporting the efficacy and efficiency of the Titan SGS Stapler.
Understanding the Recent Sell-off in Teleflex Incorporated Shares In the trading week that concluded on July 19, 2024, shares of Teleflex Incorporated (NYSE: TFX) have exhibited considerable volatility. Throughout this period, the stock has been affected by broader market trends while also facing challenges intrinsic to the company and its competitive landscape. The week included contrasting performance days, highlighting a nuanced financial environment for investors.On July 19, Teleflex s shares inched 0.69% higher to $221.79, which, on the surface, might signal a positive momentum during an otherwise poor trading session for the overall stock market. The SandP 500 Index fell by 0.71% to 5,505.00, emphasizing that even a minor uptick in Teleflex s shares was a noteworthy achievement amid a bearish market sentiment. However, despite this temporary rise, the company s stock has been trailing not just the market averages but also experiencing underperformance when compared to its competitors throughout the week.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
